期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

RRM1表达与上皮性卵巢癌预后的相关性分析 被引量：1

下载PDF
导出
摘要 目的探讨核糖核苷酸还原酶大亚基(RRM1)在上皮性卵巢癌中的表达及其预后意义。方法采用免疫组化PV-6000二步法在62例上皮性卵巢癌组织中检测RRM1蛋白的表达,用Kaplan-Meier生存曲线和COX回归分析研究RRM1与上皮性卵巢癌预后的关系。结果 RRM1蛋白阳性表达率低分化卵巢癌组高于高、中分化卵巢癌组(P<0.05);在早期上皮性卵巢癌患者中,RRM1阳性表达者生存率比阴性表达者高(P<0.05);而在晚期上皮性卵巢癌患者中,RRM1阳性表达者生存率低(P<0.05);RRM1阳性表达+癌组织低分化为卵巢癌总生存期的影响因素,RRM1阳性表达+癌组织低分化者死亡危险度是非RRM1阳性表达+癌组织低分化者的4.252倍。结论 RRM1对上皮性卵巢癌诊断及预后评估具有一定的价值。
作者 卢飞飞 任婧婧 刘宁 王黎明 王言奎 孙显璐
机构地区 青岛大学医学院附属医院
出处 《山东医药》 CAS 北大核心 2011年第13期49-50,共2页 Shandong Medical Journal
关键词 核苷酸还原酶类 卵巢肿瘤 预后
分类号 R730.7 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Gautam A,Li ZR,Bepler G.RRM1-induced metastasis suppression through PTEN-regulated pathways[J].Oncogene,2003,22(14):2135-2142.
  • 2Olaussen KA,Dunant A,Fouret P,et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,355(10):983-991.
  • 3Bepler G,Zheng Z,Gautam A,et al.Ribonucleotide reductase M1 gene promoter activity,polymorphisms,population frequencies,and clinical relevance[J].Lung Cancer,2005,47(2):183-192.
  • 4Zheng Z,Chen T,Li X,et al.DNA synthesis and repair genes RRM1 and ERC-C1 in lung cancer[J].N Engl J Med,2007,356(8):800-808.
  • 5Bepler G,Sharma S,Cantor A,et al.RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer[J].J Clin Oncol,2004,22(10):1878-1885.
  • 6陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量：57
  • 7Rosell R,Danenberg KD,Alberola V,et al.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2004,10(4):1318-1325.
  • 8HenseI M,Weiss A,Sinnhp A,et al.p53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support[J].Int J Cancer,2002,100(3):290-296.
  • 9Souglakos J,Boukovinas I,Taron M,et al.Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcin-oma patients treated with docetaxel/gemcitabine[J].Br J Cancer,2008,98(10):1710-1715.
  • 10Gabriella F,Valentina M,Sara N,et al.Expression of nucleoside transporters,deoxycitidine kinase,ribonucleotide reductase regulatory subunits,and gemcitabine catabolic enzymes in primary ovarian cancer[J].Cancer Chemother Pharmacol,2010,65(4):679-686.

二级参考文献10

  • 1MOUNTAIN C F.Revisions in the International system for staging lung cancer[J].Chest,1997,111(6):1710-1717.
  • 2MOUNTAIN CF,DRESLER CM.Regional lymph node classification for lung cancer staging[J].Chest,1997,111(6):1718-1723.
  • 3SIMON G R,SHARMA S,CANTOR A,et al.ERCCl expression is a predictor of survival in resected patients with non-small cell lung cancer[J].Chest,2005,127(3):978-983.
  • 4DE LAAt W L,JASPERS NG,HOEIJMAKERS JH.Molecular mechanism of nueleotide excision repair[J].Certes Dev,1999,13(7):768-785.
  • 5ROSELL R,COBO M,ISLA D,et al,Phannscogenomics and gemcitabine[J].Ann Oncol,2006,17(5):13-16.
  • 6TARON M,ROSELL R.,FELIP E,et al.BRCAI mRNA expmssion levels as an indicator of chemoresistance in lung caner[J].Hum Mol Cenet,2004,13(20):2443-2449.
  • 7LORD R V,BRABENDER J,GANDARA D,et al.Low ERCCI expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung Cancer[J].Clin Cancer Res,2002,8(7):2286-2291.
  • 8DAVIDSON J D,MA L,FLAGELLA M,et al.An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J].Cancer Res,2004,64(11):3761-3766.
  • 9ROSELL R,DANENBERG K D,ALBEROLA V,et al.Ribonuclcotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2004,10(4):1318-1325.
  • 10BEPLER G,GAUTAM A,MCINTYRE L M,et al.Prognostic signitlcance of molecular genetic aberrations on chromosome segment 11P15.5 in non-small-cell lung cancer[J].J Clin Oncol,2002,20(5):1353-1360.

共引文献56

同被引文献11

  • 1丰有吉,主编.妇产科学[M].北京:人民卫生出版社.2007:322-324.
  • 2陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量：57
  • 3Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer [J]. Lancet,2014,384(9951) ,1376-1388.
  • 4Jelovac D,Armstrong DK. Recent progress in the diagno- sis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011,61(3) : 183-203.
  • 5Rosell R, Crino L, Danenberg K. Targeted therapy in combination with gemeitabine in non-small cell lung cancer[J]. Semin Oncol, 2003,4 (Suppl 10) : 19-25.
  • 6Besse B, Olaussen KA,Soria J'C. ERCC1 and RRMl:read-y for prime time. J Clin Oncol, 2013, 31 (8): 1050- 1060.
  • 7Dumontet C, Isaac S, Souquet P J, et al. Expression of class I]l-tubulin in Non-small cell lung cancer is correlation with resistance to taxane chemotherapy. Bull Cancer, 2005,92(2) :E26 30.
  • 8Ferrandina G, Mey V, Nannizzi S, et al. Expression of nu cleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer[J]. Cancer Chemother Pharmacol, 2010,65 (4) . 679-686.
  • 9Zhou B,Su L, Hu S, et al. A small molecule blocking ri- bonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance[J]. Cancer Res, 2013,73 (21) : 6484-6493.
  • 10王慧敏,冯久贤,张雪艳,杨晓华,何卫中,沙慧芳,韩宝惠.ERCC1、RRM1和p53表达与Ⅰ-Ⅱ期肺癌术后预后相关性分析[J].中国肺癌杂志,2009,12(5):387-395. 被引量：12

引证文献1

山东医药
2011年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部